Status: Not yet recruiting
MT-601 Administered To Patients With Locally Advanced Unresectable or Metastatic Pancreatic Cancer
The goal of this clinical trial is to assess safety and tolerability of escalating doses of MT-601 administered during the off week of chemotherapy regimen for patients with pancreatic cancer. The main question\[s\] it aims to answer are: safety and efficacy • overall response rate and duration of response. Participants will meet all applicable inclusion criteria prior to chemotherapy and must agree to provide apheresis material.
Participants needed: 38
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Marker Therapeutics, Inc.Updated: May 13, 2026Locations: 1
Eligibility criteria
Informed Consent [+15]
Known CNS metastases or meningeal carcinomatosis unless treated and controlled f... [+12]